{"nctId":"NCT05569954","briefTitle":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","startDateStruct":{"date":"2022-11-07","type":"ACTUAL"},"conditions":["Pneumococcal Disease"],"count":1484,"armGroups":[{"label":"V116","type":"EXPERIMENTAL","interventionNames":["Biological: V116"]},{"label":"PPSV23","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: PPSV23"]}],"interventions":[{"name":"V116","otherNames":["Pneumococcal 21-valent Conjugate Vaccine"]},{"name":"PPSV23","otherNames":["PNEUMOVAX™23"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For females, is not pregnant or breastfeeding and is either not a woman of childbearing potential (WOCBP) or is a WOCBP and uses acceptable contraception/abstinence; and has medical, menstrual, and recent sexual activity history reviewed by the investigator to decrease the chance of inclusion of an early undetected pregnancy\n\nExclusion Criteria:\n\n* Has a history of invasive pneumococcal disease (IPD) \\[positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site\\] or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1)\n* Has a known hypersensitivity to any component of V116 or PPSV23, including diphtheria toxoid\n* Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease\n* Has a coagulation disorder contraindicating IM vaccination\n* Had a recent febrile illness (defined as oral or tympanic temperature ≥100.4°F \\[≥38.0°C\\] or axillary or temporal temperature ≥99.4°F \\[≥37.4°C\\]) or received antibiotic therapy for any acute illness occurring \\<72 hours before receipt of study vaccine\n* Has a known malignancy that is progressing or has required active treatment \\<3 years before enrollment\n* Received prior pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol\n* Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention ≥14 days before receipt of study vaccine\n* Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease\n* Received any nonlive vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤30 days after receipt of study vaccine (inactivated influenza and SARS-CoV2 vaccines may be acceptable)\n* Received any live virus vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine\n* Received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of pain/tenderness, redness/erythema, and swelling. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \\& Nurminen method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"35.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Systemic AEs","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C). 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \\& Nurminen method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"15.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)","description":"An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \\& Nurminen method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Serotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116","description":"Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs), and they hypothesis test (1-sided p-value), were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230.4","spread":null},{"groupId":"OG001","value":"211.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4876.7","spread":null},{"groupId":"OG001","value":"3314.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3379.6","spread":null},{"groupId":"OG001","value":"2882.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7346.6","spread":null},{"groupId":"OG001","value":"6545.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4382.9","spread":null},{"groupId":"OG001","value":"2818.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3711.1","spread":null},{"groupId":"OG001","value":"1809.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3031.8","spread":null},{"groupId":"OG001","value":"1854.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8215.7","spread":null},{"groupId":"OG001","value":"4060.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2670.0","spread":null},{"groupId":"OG001","value":"1879.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6966.1","spread":null},{"groupId":"OG001","value":"4208.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4724.1","spread":null},{"groupId":"OG001","value":"3084.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15497.3","spread":null},{"groupId":"OG001","value":"17483.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3193.9","spread":null},{"groupId":"OG001","value":"964.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6746.5","spread":null},{"groupId":"OG001","value":"1462.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7604.8","spread":null},{"groupId":"OG001","value":"2605.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6675.4","spread":null},{"groupId":"OG001","value":"1482.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4804.2","spread":null},{"groupId":"OG001","value":"837.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2252.6","spread":null},{"groupId":"OG001","value":"137.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4568.0","spread":null},{"groupId":"OG001","value":"1346.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5040.7","spread":null},{"groupId":"OG001","value":"423.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10707.5","spread":null},{"groupId":"OG001","value":"1735.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116","description":"The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the unique pneumococcal serotypes contained in V116 was determined. The 9 unique pneumococcal serotypes in V116 are as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"53.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null},{"groupId":"OG001","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"20.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null},{"groupId":"OG001","value":"44.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"18.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific Cross-Reactive OPAs","description":"OPA induced by serotypes 6A and 15C in V116 but cross-reactive to serotypes 6C and 15B, respectively, were measured. The percentage of participants with ≥4-fold rise from baseline in serotype-specific cross-reactive OPAs was determined. Point estimate, 95% CI, and p-value are based on the Clopper-Pearson method. Per protocol, this outcome measure was not planned or analyzed in the PPSV23 study arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-Specific Geometric Mean Fold Rise (GMFR) of OPA GMTs for All Serotypes in V116","description":"The GMFR from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined using MOPA. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null},{"groupId":"OG001","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":null},{"groupId":"OG001","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.2","spread":null},{"groupId":"OG001","value":"58.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null},{"groupId":"OG001","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.9","spread":null},{"groupId":"OG001","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for All Serotypes in V116","description":"The GMCs for serotype-specific IgG antibodies for all serotypes in V116 were determined using pneumococcal electrochemiluminescence (PnECL). The GMC ratio estimation and 95% CI were calculated using a cLDA method. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":null},{"groupId":"OG001","value":"0.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.35","spread":null},{"groupId":"OG001","value":"5.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.83","spread":null},{"groupId":"OG001","value":"11.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.21","spread":null},{"groupId":"OG001","value":"7.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.05","spread":null},{"groupId":"OG001","value":"7.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.83","spread":null},{"groupId":"OG001","value":"4.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":null},{"groupId":"OG001","value":"1.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.39","spread":null},{"groupId":"OG001","value":"6.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.54","spread":null},{"groupId":"OG001","value":"6.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.97","spread":null},{"groupId":"OG001","value":"12.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.32","spread":null},{"groupId":"OG001","value":"3.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.12","spread":null},{"groupId":"OG001","value":"15.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.79","spread":null},{"groupId":"OG001","value":"1.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.98","spread":null},{"groupId":"OG001","value":"2.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.27","spread":null},{"groupId":"OG001","value":"5.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.48","spread":null},{"groupId":"OG001","value":"0.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.21","spread":null},{"groupId":"OG001","value":"0.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.74","spread":null},{"groupId":"OG001","value":"1.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.52","spread":null},{"groupId":"OG001","value":"0.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.48","spread":null},{"groupId":"OG001","value":"0.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.26","spread":null},{"groupId":"OG001","value":"1.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-Specific GMFR of IgG GMCs for All Serotypes in V116","description":"The GMFR from baseline in GMCs for serotype-specific IgG antibodies for all serotypes in V116 was determined using PnECL. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":null},{"groupId":"OG001","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":null},{"groupId":"OG001","value":"14.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific OPA GMTs for All Serotypes in V116","description":"The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined with MOPA. The within-group CIs were calculated based on the Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"66.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null},{"groupId":"OG001","value":"69.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null},{"groupId":"OG001","value":"85.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null},{"groupId":"OG001","value":"66.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"90.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"71.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","spread":null},{"groupId":"OG001","value":"64.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null},{"groupId":"OG001","value":"58.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null},{"groupId":"OG001","value":"67.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.2","spread":null},{"groupId":"OG001","value":"70.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"53.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null},{"groupId":"OG001","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"20.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null},{"groupId":"OG001","value":"44.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"18.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific IgG GMCs for All Serotypes in V116","description":"The percentage of participants with ≥4-fold rise from baseline in serotype-specific IgG GMCs for all serotypes in V116 was determined using PnECL. The within-group CIs were calculated based on the Clopper-Pearson method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":null},{"groupId":"OG001","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null},{"groupId":"OG001","value":"79.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":null},{"groupId":"OG001","value":"86.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"83.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"81.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.8","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null},{"groupId":"OG001","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":null},{"groupId":"OG001","value":"58.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"77.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"83.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.4","spread":null},{"groupId":"OG001","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"34.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"72.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null},{"groupId":"OG001","value":"29.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"33.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":739},"commonTop":["Injection site pain","Fatigue","Headache","Injection site erythema","Myalgia"]}}}